Avant Technologies and Austrianova Secure Exclusive License for Klotho Producing Cell Line to Advance Anti-Aging Therapies
Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cellbased therapies for diabetes and age-related disorders, today announced that its 50/50 joint venture (Klothonova) with Austrianova has entered into an exclusive, worldwide License Agreement with Klothea Bio, Inc. The license agreement, effective immediately, grants Klothonova exclusive global rights to develop, manufacture, and commercialize Klothea Bio’s proprietary Klotho producing cells, encapsulated using Austrianova’s proprietary Cell-in-a-Box® technology, for the treatment of diseases and conditions in humans and animals.
